Ads
related to: simvastatin dangers in dogs treatment schedule 2 drug list cost
Search results
Results From The WOW.Com Content Network
Abuse of the drug or other substances may lead to severe psychological or physical dependence. The complete list of Schedule II substances is as follows. The Administrative Controlled Substances Code Number and Federal Register citation for each substance is included.
Simvastatin also reduced the numbers of other events like heart attacks, strokes, and revascularizations and MI significantly. [11] The Heart Protection Study evaluated the effects of simvastatin in people with risk factors including existing cardiovascular disease, diabetes, or stroke, but having relatively low LDL cholesterol. In this trial ...
The United States Food and Drugs Administration is warning pet owners about a common medication given to pets to treat arthritis. The F.D.A. now says that the drug Librela may be associated with ...
This article lists veterinary pharmaceutical drugs alphabetically by name. Many veterinary drugs have more than one name and, therefore, the same drug may be listed more than once. Abbreviations are used in the list as follows: INN = International Nonproprietary Name; BAN = British Approved Name; USAN = United States Adopted Name
Simvastatin: No tumorigenic effect was seen in a 72-week carcinogenicity study using mice at the low dose levels. However, at the higher dose levels (eight and 16 times the human dose equivalent), liver carcinomas and adenomas, lung adenomas, and adenomas of the Harderian gland occurred.
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
Guidelines by the American College of Cardiology and the American Heart Association recommend statin treatment for primary prevention of cardiovascular disease in adults with LDL cholesterol ≥ 190 mg/dL (4.9 mmol/L) or those with diabetes, age 40–75 with LDL-C 70–190 mg/dL (1.8–4.9 mmol/dL); or in those with a 10-year risk of developing ...
While there have been concerns about side-effects associated with statins (myopathy and rhabdomyolysis), these were rare in this study. [citation needed] The number needed to treat in the study was 57 to postpone one death and 19 to prevent one cardiovascular "event" (in those taking the drug simvastatin for 5 years). There was no mortality ...